Table 3.
T cell subset | OS | Meana Baseline | Standard Error | P |
---|---|---|---|---|
CD3+CD4+CD137+ | < 24 mo. | 0.17 | 0.20 | 0.04 |
> 24 mo. | 0.36 | 0.29 | ||
CD3+CD4+CD45RO+BTLA+ | < 24 mo. | 2.27 | 0.58 | 0.05 |
> 24 mo. | 6.64 | 2.25 | ||
CD3+CD8+CD45RA+CTLA-4+ | < 24 mo. | 2.06 | 0.55 | 0.02 |
> 24 mo. | 0.55 | 0.14 | ||
CD3+CD4+IL-17+ | < 24 mo. | 0.34 | 0.09 | 0.02 |
> 24 mo. | 1.74 | 0.60 | ||
CD3+CD8+IL-17+ | < 24 mo. | 0.38 | 0.10 | 0.02 |
> 24 mo. | 1.41 | 0.44 | ||
T cell subset | OS | Meana W12 | Standard Error | P |
CD3+ CD45RO+CD62L+ | < 24 mo. | 4.39 | 1.55 | 0.02 |
> 24 mo. | 12.36 | 3.18 | ||
CD3+ CD4+CD45RO+CD62L+ | < 24 mo. | 5.40 | 1.82 | 0.02 |
> 24 mo. | 14.34 | 3.24 | ||
CD3+CD4+CD45RA+BTLA+ | < 24 mo. | 4.63 | 1.28 | 0.01 |
> 24 mo. | 1.08 | 0.99 | ||
CD3+CD8+CD45RA+CTLA-4+ | < 24 mo. | 2.04 | 0.52 | 0.007 |
> 24 mo. | 0.41 | 0.11 |
The association between the frequency of circulating T cell subsets and long-term survival (OS>24 mo) of MM patients has been analyzed and the statistically significant results have been reported in the table. a: mean of the percentage of positive cells in PBMCs from melanoma patients; mo.: months.